Evidence map›Paper›PMID 42159407›Full record

ReviewJournal of Parkinson's disease2026

The Global Parkinson's Genetics Program (GP2): Advancing genetic discovery and capacity building worldwide.

Victor Flores-Ocampo, Alexandra Zirra, Yi Wen Tay, Vesna van Midden, Ignacio F Mata, Alastair J Noyce, Maria Teresa Periñan, Global Parkinson's Genetics Program (GP2)

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Does genetic testing remain relevant in advanced Parkinson's disease?Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Victor Flores-OcampoSchool of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.ORCID 0009-0006-5562-1260
Alexandra ZirraCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.ORCID 0000-0003-3901-5456
Yi Wen TayDepartment of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Vesna van MiddenDepartment of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.ORCID 0000-0003-4653-8503
Ignacio F MataGenome Sciences and Systems Biology, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0003-1198-0633
Alastair J NoyceCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Maria Teresa PeriñanCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Global Parkinson's Genetics Program (GP2)

Funding

Genome wide SNP analysis in Parkinson's diseaseZIAAG000949 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2024
$12.6M
Intramural NIH HHS ZIA AG000949
6 · The paper itself

Abstract

The Global Parkinson's Genetics Program (GP2) is an international initiative funded by Aligning Science Across Parkinson's (ASAP), in partnership with the Michael J Fox Foundation for Parkinson's Research (MJFF), to accelerate genetic discovery and improve ancestral representation in Parkinson's disease (PD) and related diseases through collaboration, open data sharing, and research capacity building. Since its launch in 2020, GP2 has assembled the largest and most ancestrally diverse PD dataset to date, integrating genotyping, sequencing, and harmonized clinical data from over 240 cohorts worldwide. Through its structured monogenic and complex disease networks, the program spans rare and common variant discovery to advance understanding of PD genetics. Recent GP2-supported studies have identified more than 50 novel genetic risk factors for PD, including a remarkably common

Indexed as

Capacity BuildingGenetic Predisposition to DiseaseParkinson DiseaseGenome-Wide Association StudyHumanscapacity buildinggeneticsParkinson's diseaseresearch trainingunderrepresented populations

Identifiers

PMID42159407
PMCPMC13435180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.